FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to immunology and oncology, and aims at preventing or treating cancer or infectious diseases. Presented is a human programmed cell death (PD-L1) antibody ligand or its antigen-binding fragment coding its nucleic acid, a vector containing said nucleic acid, a cell transformed with said vector, method of producing said antibody or its antigen-binding fragment and composition containing said composition for preventing or treating cancer or infectious diseases.
EFFECT: group of inventions enables improving the activity and effect of inhibited tumour-specific T-lymphocyte cells by inhibiting their functions by using monoclonal antibodies against PD-1 or its PD-L1 ligand in order to obtain anti-cancer effects.
11 cl, 13 tbl, 12 ex, 19 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| ANTIBODY AGAINST TIE-2 AND ITS USE | 2020 |
|
RU2795455C2 |
| HUMANIZED ANTIBODIES AND ANTIBODIES WITH MATURE AFFINITY AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2748943C2 |
| COMBINATIONS OF ANTIBODIES FOR TREATING CANCER IN SPECIFIC PATIENTS | 2020 |
|
RU2816531C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| NEW VERSIONS OF HYALURONIDASE WITH IMPROVED STABILITY AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2021 |
|
RU2811464C2 |
